|
|
|
|
Learn how process design and cross-functional collaboration mitigate risks and accelerate the path from early development to FIH manufacturing through real-world case studies of practical approaches.
|
|
|
|
|
Andrew Brown, Head of Global Process Development Support at Lonza, answers questions about an integrated drug substance and drug product CMC strategy for novel molecular formats and other recombinant proteins. Brown also reviews technical case studies that demonstrate tailored, product-specific solutions that enable acceleration into the clinic.
|
|
|
|
|
Gain expert insights on how tailored approaches and innovative technologies enable fast and flexible development workflows, supporting rapid therapeutic breakthroughs. Explore an approach to fast-track your material supply for toxicological studies, and discover strategies to streamline the path to clinical trials for novel biotherapeutics.
|
|
|
|
|
Accelerating the timeline to tox material can significantly enhance the drug development process, enabling faster IND submissions and providing crucial time savings for toxicology studies.
|
|
|
